Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function英文教材.PDFVIP

Molecular Medicine Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport F function O O Running head: Lapatinib antagonizes multidrug resistance R Author list: Shao-lin Ma, Ya-peng Hu, Fang Wang, Zhen-cong Huang, Yi-fan Chen， P Xiao-kun Wang, Li-wu Fu* D Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology E in South China, Cancer Center of Sun Yat-Sen University, Guangzhou, China 510060 T C Keywords: ABC transporters; MRP1; LRP; AKT; ERK1/2 E R * Correspondence to: Li-wu Fu, MD, PhD. Collaborative Innovation Center for Cancer Medicine, State Key R Laboratory of Oncology in South China, Cancer Center of Sun Yat-Sen University, 651 O Dongfeng East Road, Guangzhou, China 510060. Phone: +86-(20)-873-431-63; Fax : C +86-(20)-873-431-70 ； E-mail: Fulw@ N U Molecular Medicine Abstract Lapatinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2). Lapatinib F can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and O ABCG2) which are the major mechanism responsible for multidrug resistance (MDR) in O cancer. In this study, we investigated the effect of lapatinib on multidrug R resistance-associated protein 1(MRP 1/ABCC1), MRP2 (ABCC2), MRP4 (ABCC4) and P